Results 41 to 50 of about 37,793 (186)

An Analysis of Remdesivir Patenting

, 2020
Pharmaceutical patents are categorized into primary patents and secondary patents. Primary patents refer to compound patents, while secondary patents mainly include crystalline form patents, process patent, formulation patent and method of use patent. In
CHANG, Tingbin, WANG, Zhong
core   +1 more source

Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate

Journal of Microbiology, Immunology and Infection, 2023
Background: Despite increasing concerns about the association between remdesivir and bradycardia in severe coronavirus disease 2019 (COVID-19) patients receiving remdesivir, information on its clinical course and precipitating factors is limited. Our aim
Yan-Zuo Chen, Ming-Shen Lin, Yi-Ping Lin, Yi-Zhan Liu, Chia-Jui Yang   +4 more
doaj   +1 more source

The Ethical Allocation of Remdesivir Within Hospitals

, 2021
Recent evidence has shown that remdesivir may shorten length of hospital stay and recovery in COVID-19 patients. Many hospitals are experiencing shortages of remdesivir and are being forced to determine systems for the ethical allocation of this drug ...
Comer, Amber R.
core   +1 more source

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study

Infectious Diseases and Therapy, 2023
Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes   +17 more
doaj   +1 more source

The effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19

Asian Journal of Medical Sciences, 2021
Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers. Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate ...
Sanjana Rai , Dyna Jones , Chinnappa Anjanappa Jayashankar , Venkata Bharat Kumar Pinnelli , Eashwer Manpreeth , Venkata Sai Raghava Prashanthi Seetha   +5 more
doaj   +1 more source

Remdesivir vs. covid-19

, 2020
COVID-19 is a disease caused by the SARS-COV-2 virus. The virus first appeared in China in the city of Wuhan. The virus that infected other countries as well. It is a threat to the health and life of society.
Oleś, Izabela
core   +1 more source

Remdesivir for severe covid-19: a clinical practice guideline [PDF]

, 2020
Clinical question What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.
Kanda, Seema, Appiah, John Adabie, Zeng, Linan, Kwizera, Arthur, Vandvik, Per Olav, Ge, Long, Kurian, Linda, Ye, Zhikang, Bartoszko, Jessica, Gershengorn, Hayley B, Geduld, Heike, Kawano-Dourado, Leticia, Silvestre, Maria Asuncion, Siemieniuk, Reed, Guyatt, Gordon, Qadir, Nida, Agarwal, Arnav, Huang, Minhua, Manai, Hela, Agoritsas, Thomas, Rochwerg, Bram, Brignardello-Petersen, Romina, Gershengorn, Hayley B., Zeraatkar, Dena, Ergan, Begum, Lamontagne, François, Leo, Yee-Sin, Murthy, Srinivas   +27 more
core   +1 more source

Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial [PDF]

, 2022
We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19.
Paukkeri, Erja Leena, Haukka, Jari K., Mustonen, Jussi M.J., Parkkila, Seppo, Rutanen, Taija, Haukka, Jari K, Mustonen, Jussi M. J., Renner, Andreas, Kreivi, Hanna Riikka, Guyatt, Gordon H, Laakkonen, Sanna, Nevalainen, Olli P O, Kuutti, Pauliina, Horstia, Saana, Perola, Markus, Tikkinen, Kari A. O., Paukkeri, Erja-Leena, Kreivi, Hanna-Riikka, Savolainen, Joni, Nevalainen, Olli P. O., Mustonen, Jussi M J, Kalliala, Ilkka E.J., Kalliala, Ilkka E J, ,, Tikkinen, Kari A O, Rosberg, Tuomas, Rutanen, Jarno, Guyatt, Gordon H., Pourjamal, Negar, Kalliala, Ilkka E. J., Ansakorpi, Hanna, Paajanen, Juuso, Nevalainen, Olli P.O., Tikkinen, Kari A.O.   +33 more
core   +1 more source

Remdesivir and its antiviral activity against COVID-19: A systematic review

Clinical Epidemiology and Global Health, 2021
Background: The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. Methods: Available publications were systematically explored on some databases and gray literature was examined.
Andri Frediansyah, Firzan Nainu, Kuldeep Dhama, Mudatsir Mudatsir, Harapan Harapan   +4 more
doaj   +1 more source

PPA-2021-0023 - Remdesivir Overview

, 2022
By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19.
Sandro G Viveiros Rosa (12694006), Wilson C. Santos (7624058)   +1 more
core   +1 more source